Program
quizartinib
Also written as “Quizartinib”, “AC220” and “Quizartinib High Dose”.
Its studies are mostly in Leukemia, Myeloid, Acute, led by 2 companies.
Drug pageQuizartinib: every studyAll 37 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Daiichi Sankyo | 214 open or running | phase 3since Jan 15, 2014 | Apr 17, 2007 | May 1, 2027phase 2 · NCT03793478 |
| Kura Oncologyits history only | 11 open or running | phase 1since Feb 9, 2023 | Feb 9, 2023 | Apr 2030phase 1 · NCT05735184 |
Also a collaborator on its studies: Quotient Sciences and Ambit Biosciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Daiichi Sankyo only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Apr 17, 2007.
- Jan 15, 2014Phase 3 study in Leukemia, Myeloid, AcuteNCT02039726 · 367 enrolled · United States, Australia, Belgium and more
- Jan 22, 2016Phase 3 study in Leukemia, Myeloid, AcuteNCT02668653 · 539 enrolled · United States, Argentina, Australia and more
- Feb 2, 2016Phase 1 study in Leukemia, Myeloid, AcuteNCT02675478 · 17 enrolled · Japan
- Jul 13, 2016Phase 1 study in Leukemia, Myeloid, AcuteNCT02834390 · 7 enrolled · Japan
- Dec 5, 2016Phase 2 study in Leukemia, Myeloid, AcuteNCT02984995 · 37 enrolled · Japan
- May 17, 2018Phase 1 study in Leukemia, Myeloid, AcuteNCT03552029 · 10 enrolled · United States
- Oct 18, 2018Phase 1 study in Leukemia, Myeloid, AcuteNCT03723681 · 7 enrolled · China
- Jan 2, 2019Phase 2 study in Leukemia, Myeloid, AcuteNCT03793478 · 65 enrolled · United States, Belgium, Canada and more
- Jul 2, 20202 phase 1 studiesNCT04459598, NCT04473664
- Jul 2, 2020Early phase 1 study in Healthy SubjectsNCT04459585 · 20 enrolled · United States
- Mar 5, 2021Phase 1 study in Healthy SubjectsNCT04796831 · 8 enrolled · United Kingdom
- Aug 14, 2024Phase 3 study in LeukemiaNCT06578247 · 700 enrolled · United States, Australia, Austria and more
- Dec 13, 20243 phase 1 studiesNCT06772246, NCT06740825, NCT06740799
- Feb 7, 2025Phase 2 study in Leukemia, Myeloid, AcuteNCT06824168 · 130 planned · United States, Australia, Brazil and more
Ahead
- May 1, 2027Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT03793478
- Jun 6, 2028Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT06824168
- Jun 26, 2030Primary completion: phase 3 study in LeukemiaNCT06578247
TargetBeta
“Macrophage colony stimulating factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor”ChEMBL 37, by rule
Studies
All 21 Daiichi Sankyo leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06824168Leukemia, Myeloid, Acute · United States, Australia, Brazil and more | 2 | Recruiting | Jun 6, 2028 | 130 |
| NCT06772246Healthy Subjects · United States | 1 | Completed | Jun 12, 2025 | 70 |
| NCT06740825Healthy Subjects · United States | 1 | Completed | Dec 9, 2024 | 32 |
| NCT06740799Hepatic Impairment · United States | 1 | Recruiting | Oct 31, 2026 | 12 |
| NCT06578247Leukemia · United States, Australia, Austria and more | 3 | Active, not recruiting | Jun 26, 2030 | 700 |
| NCT04796831Healthy Subjects · United Kingdom | 1 | Completed | Jun 11, 2021 | 8 |
| NCT04473664Hepatic Impairment · United States | 1 | Completed | Jul 22, 2021 | 12 |
| NCT04459598Healthy Subjects · United States | 1 | Completed | Oct 14, 2020 | 32 |
| NCT04459585Healthy Subjects · United States | Early 1 | Completed | Oct 20, 2020 | 20 |
| NCT03793478Leukemia, Myeloid, Acute · United States, Belgium, Canada and more | 2 | Active, not recruiting | May 1, 2027 | 65 |
| NCT03723681Leukemia, Myeloid, Acute · China | 1 | Completed | Mar 3, 2022 | 7 |
| NCT03552029Leukemia, Myeloid, Acute · United States | 1 | Terminated | Apr 1, 2021 | 10 |
| NCT02984995Leukemia, Myeloid, Acute · Japan | 2 | Completed | Mar 28, 2018 | 37 |
| NCT02834390Leukemia, Myeloid, Acute · Japan | 1 | Completed | Oct 19, 2017 | 7 |
| NCT02675478Leukemia, Myeloid, Acute · Japan | 1 | Completed | Nov 13, 2018 | 17 |
| NCT02668653Leukemia, Myeloid, Acute · United States, Argentina, Australia and more | 3 | Completed | Aug 13, 2021 | 539 |
| NCT02039726Leukemia, Myeloid, Acute · United States, Australia, Belgium and more | 3 | Completed | Feb 22, 2018 | 367 |
| NCT01565668Leukemia, Myeloid, Acute · United States, France, Italy and more | 2 | Completed | Mar 2015 | 76 |
| NCT01468467Leukemia, Myeloid, Acute · United States | 1 | Completed | Mar 2015 | 13 |
| NCT01390337Leukemia, Myeloid, Acute · United States | 1 | Completed | Feb 2015 | 19 |
| NCT00462761Leukemia, Myeloid, Acute · United States, Georgia | 1 | Completed | Mar 2009 | 76 |
How it is read
Names in the registry
- “Quizartinib”, 15 entries
- “AC220”, 5 entries
- “Quizartinib High Dose”, 1 entry
- “Quizartinib Low Dose”, 1 entry
- “Quizartinib dihydrochloride”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 15 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.